UK Clinical Pharmacy Association

Verapamil

Issues for surgery

For treatment of hypertension – loss of blood pressure (BP) control if omitted.

For treatment of angina – exacerbation of angina if omitted.

For treatment of arrhythmias – exacerbation of arrhythmias if omitted.

For treatment of cluster headache - exacerbation of symptoms if omitted.

Risk of hypotension when continued.

Advice in the perioperative period

Elective and emergency surgery 

Continue – monitor BP and heart rate.

Post-operative advice

Restart post-operatively when next dose is due.

Monitor BP and heart rate.

Interactions with common anaesthetic agents

Inhalational Anaesthetics 

See also Hypotension below.

Verapamil may reduce the minimum alveolar concentration (MAC) of inhalational anaesthetics by up to 20%.

Hypotension

Verapamil can increase the risk of hypotension when used concomitantly with remifentanil or inhalational / intravenous anaesthetics.

Concomitant use of verapamil with alfentanil / fentanyl may increase the risk of hypotension.

Bradycardia

Verapamil can increase the risk of bradycardia when used concomitantly with the following:

  • alfentanil, fentanyl or remifentanil (also see below)
  • neostigmine
  • propofol
  • suxamethonium

Alfentanil, fentanyl and remifentanil 

See also Bradycardia and Hypotension above.

Verapamil may increase the effects of alfentanil, fentanyl and remifentanil – monitor for opioid adverse effects (e.g. prolonged sedation, respiratory depression) and adjust dose as necessary.

Midazolam

Verapamil may increase the plasma concentration and prolong the half-life of midazolam. Care should be taken when prescribing short-acting benzodiazepines metabolised by the CYP3A4 pathway. Consider using a lower initial dose (a 50% reduction has been suggested).

Neuromuscular blocking drugs (NMBDs)

Verapamil may prolong neuromuscular blockade when used concomitantly with NMBDs. The clinical significance is unknown, but bear the potential interaction in mind in case of unexpected response to treatment.

Dantrolene

Intravenous dantrolene potentially increases the risk of acute hyperkalaemia and cardiovascular collapse when given with verapamil. It is recommended that co-administration of verapamil with dantrolene should be avoided.

Interactions with other common medicines used in the perioperative period

Hypotension

Verapamil can increase the risk of hypotension when used concomitantly with droperidol or prochlorperazine.

Oxycodone

Verapamil are predicted to increase the exposure to oxycodone – monitor for prolonged sedation and respiratory depression. The dose of oxycodone may need to be reduced.

Macrolide antibiotics

Macrolide antibiotics (e.g. clarithromycin, erythromycin), which are inhibitors of CYP3A4, may increase the effects of verapamil leading to hypotension and bradycardia. Monitor the patient and consider reducing the dose of the verapamil if necessary.

Whilst single surgical prophylactic doses should not pose a problem, continued post-operative treatment may require close monitoring. Consult current product literature.

Further information

None relevant.

References

The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal. 2014; 35:2383-2431

Scarth E, Smith S. Drugs in Anaesthesia and Intensive Care, 5th Edition. Oxford University Press; 2016

British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http://www.medicinescomplete.com [Accessed on 12th April 2019]

Baxter K, Preston CL (eds), Stockley’s Drug Interactions (online) London: Pharmaceutical Press. http://www.medicinescomplete.com [Accessed on 12th April 2019]

Dantrolene Sodium. In: Brayfield A (Ed), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. http://www.medicinescomplete.com [Accessed 9th October 2019]

Diazepam. In: Brayfield A (Ed), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. http://www.medicinescomplete.com [Accessed 12th April 2019]

Verapamil. In: Brayfield A (Ed), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. http://www.medicinescomplete.com [Accessed 9th October 2019]

Summary of Product Characteristics – Securon SR® (verapamil). Mylan. Accessed via www.medicines.org.uk 09/10/2019 [date of revision of the text May 2017]